Latin America Diabetes Drugs Market Dynamics, Top Manufacturers Analysis, Trend and Demand, Forecast To 2024

The market for LATAM diabetes Drugs Market is USD 3.5 billion in 2017 and is expected to witness an approximate CAGR of 5% during the forecast period, primarily due to the growing geriatric population.
The diabetic prevalence is high in the countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing type 2 population in the country.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/19813
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

The gradually growing obesity rate combined with the genetic predisposition for Type 2 diabetes is acting as a prominent driver for the increase in type two diabetic population over the last 40 years.
Now close to 10% of the total population are living with diabetes in one form or the other. The diabetic patients in the LATAM region majorly type 2 patients that account for close to 90% of the total diabetic population in 2017.

Scope of the Report
The Market is segmented by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors), and by geography.

Competitive Landscape
- Novo Nordisk holds the highest market share in the Latin America diabetes drug market.
- Branded drugs of Eli Lilly & Boehringer Ingelheim Alliance is expected grow with the high CAGR of more than 15% in the forecast period

Request Discount on this report @ https://marketprognosis.com/discount-request/19813
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Key Market Trends
Oral diabetic drug has high sales
- Type 2 oral diabetic drug has high sales in this region mainly due to the low-cost factor.
- Most of the drugs are generic and so are priced way lower than branded drugs.
- Biguanides are considered to be the first class of oral drugs for type 2 patients.
- Mexico is among the top 10 countries that have the highest market value and volume for Biguanides.
- The market for the generic diabetic drug has a high potential for future growth in various countries in the LATAM region.

Brazil accounts for the highest market share in Latin Ameria diabetes drugs market
- Brazil accounts for 51% of the diabetic drug market in LATAM. In 2017, mainly due to higher consumption of insulin by type 1 patients.
- Brazil accounts for close to 78% of all the type 1 patients in the region. Basal insulin Lantus accounts for the largest share by value of 89% in 2017 in the Brazil insulin market.

Enquiry Before Buying @ https://marketprognosis.com/enquiry/19813

Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.